| Literature DB >> 20663129 |
Elke Jeschke1, Thomas Ostermann, Manuela Tabali, Horst C Vollmar, Matthias Kröz, Angelina Bockelbrink, Claudia M Witt, Stefan N Willich, Harald Matthes.
Abstract
BACKGROUND: Pharmacotherapy in the older adult is a complex field involving several different medical professionals. The evidence base for pharmacotherapy in elderly patients in primary care relies on only a few clinical trials, thus documentation must be improved, particularly in the field of complementary and alternative medicine (CAM) like phytotherapy, homoeopathy, and anthroposophic medicine. This study describes diagnoses and therapies observed in elderly patients treated with anthroposophic medicine in usual care.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20663129 PMCID: PMC2916899 DOI: 10.1186/1471-2318-10-48
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Most frequent diagnoses according to age group and gender
| Diagnosis [ICD-10] | Total [%] | Female [%] | Male [%] |
|---|---|---|---|
| Hypertensive diseases [I10-I15] | 25.1 | 23.3 | 28.6 |
| Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 19.0 | 20.8 | 15.5 |
| Mood [affective] disorders [F30-F39] | 11.9 | 13.0 | 7.2 |
| Dorsopathies [M40-M54] | 10.7 | 10.1 | 12.0 |
| Arthropathies [M00-M25] | 9.1 | 10.1 | 7.1 |
| Episodic and paroxysmal disorders* [G40-G47] | 8.3 | 9.0 | 6.8 |
| Other forms of heart disease [I30-I52] | 8.3 | 8.1 | 8.6 |
| General symptoms and signs [R50-R69] | 8.2 | 8.5 | 7.7 |
| Chronic lower respiratory diseases [J40-J47] | 8.0 | 8.1 | 7.9 |
| Diabetes mellitus [E10-E14] | 6.3 | 4.4 | 10.0 |
| Hypertensive diseases [I10-I15] | 33.6 | 31.9 | 36.6 |
| Other forms of heart disease [I30-I52] | 16.4 | 15.0 | 19.0 |
| Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 12.6 | 8.3 | 20.4 |
| Mood [affective] disorders [F30-F39] | 10.9 | 12.6 | 7.7 |
| Ischaemic heart diseases [I20-I25] | 10.6 | 10.2 | 11.3 |
| Diabetes mellitus [E10-E14] | 10.1 | 12.2 | 6.3 |
| Dorsopathies [M40-M54] | 9.8 | 11.8 | 6.3 |
| Arthropathies [M00-M25] | 9.8 | 10.6 | 8.5 |
| Chronic lower respiratory diseases [J40-J47] | 9.3 | 7.5 | 12.7 |
| Organic, including symptomatic, mental disorders** [F00-F09] | 6.8 | 6.7 | 7.0 |
| Hypertensive diseases [I10-I15] | 39.4 | 39.6 | 38.8 |
| Other forms of heart disease [I30-I52] | 32.9 | 33.3 | 22.3 |
| Ischaemic heart diseases [I20-I25] | 16.8 | 16.7 | 17.4 |
| Arthropathies [M00-M25] | 15.7 | 17.6 | 9.1 |
| Dorsopathies [M40-M54] | 12.8 | 12.3 | 14.9 |
| Episodic and paroxysmal disorders* [G40-G47] | 12.3 | 13.0 | 9.9 |
| Organic, including symptomatic, mental disorders** [F00-F09] | 11.6 | 11.1 | 13.2 |
| Osteopathies and chondropathies [M80-M94] | 9.9 | 12.3 | 1.7 |
| Chronic lower respiratory diseases [J40-J47] | 9.8 | 8.8 | 13.2 |
| Mood [affective] disorders [F30-F39] | 9.4 | 9.5 | 9.1 |
| Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 9.4 | 8.6 | 12.4 |
* including sleep disorders, ** including dementia
Figure 1Number of prescribed drugs per patient and year according to gender and age group
Therapy regimen according to consultation type, physician specialization, patient age, gender, and diagnosis
| Total | Only CAM treatment | CAM and conventional treatment combined | Only conventional treatment | ||||
|---|---|---|---|---|---|---|---|
| First | 1845 | 664 | 36.0 | 139 | 7.5 | 1042 | 56.5 |
| Follow-up | 10469 | 3094 | 29.6 | 1719 | 16.4 | 5656 | 54.0 |
| GP | 7956 | 2376 | 29.9 | 1161 | 14.6 | 4419 | 55.5 |
| Internal medicine | 2527 | 972 | 38.5 | 427 | 16.9 | 1128 | 44.6 |
| Other | 1831 | 410 | 22.4 | 270 | 14.7 | 1151 | 62.9 |
| 60-74 | 7320 | 2648 | 36.2 | 1134 | 15.5 | 3538 | 48.3 |
| 75-79 | 1762 | 409 | 23.2 | 239 | 13.6 | 1114 | 63.2 |
| > 80 | 3232 | 701 | 21.7 | 485 | 15.0 | 2046 | 63.3 |
| male | 3567 | 901 | 25.3 | 513 | 14.4 | 2153 | 60.4 |
| female | 8747 | 2857 | 32.7 | 1345 | 15.4 | 4545 | 52.0 |
| Diseases of the circulatory system [I00-I99] | 2835 | 563 | 19.9 | 424 | 15.0 | 1848 | 65.2 |
| Neoplasms [C00-D48] | 1380 | 856 | 62.0 | 137 | 9.9 | 387 | 28.0 |
| Diseases of the musculoskeletal system and connective tissue [M00-M99] | 1211 | 443 | 36.6 | 206 | 17.0 | 562 | 46.4 |
| Endocrine, nutritional, and metabolic diseases [E00-E90] | 1103 | 148 | 13.4 | 141 | 12.8 | 814 | 73.8 |
| Diseases of the nervous system [G00-G99] | 1058 | 189 | 17.9 | 119 | 11.2 | 750 | 70.9 |
| Mental and behavioural disorders [F00-F99] | 901 | 260 | 28.9 | 126 | 14.0 | 515 | 57.2 |
| Diseases of the digestive system [K00-K93] | 763 | 220 | 28.8 | 147 | 19.3 | 396 | 51.9 |
| Diseases of the respiratory system [J00-J99] | 745 | 308 | 41.3 | 155 | 20.8 | 282 | 37.9 |
| Symptoms, signs, and abnormal clinical and laboratory findings [R00-R99] | 695 | 215 | 30.9 | 133 | 19.1 | 347 | 49.9 |
| Diseases of the genitourinary system [N00-N99] | 386 | 124 | 32.1 | 50 | 13.0 | 212 | 54.9 |
| Diseases of the skin and subcutaneous tissue [L00-L99] | 376 | 136 | 36.2 | 67 | 17.8 | 173 | 46.0 |
| Injury, poisoning, and certain other consequences of external causes [S00-T98] | 263 | 80 | 30.4 | 35 | 13.3 | 148 | 56.3 |
| Certain infectious and parasitic diseases [A00-B99] | 260 | 71 | 27.3 | 62 | 23.8 | 127 | 48.8 |
| Diseases of the eye and adnexa [H00-H59] | 103 | 50 | 48.5 | 19 | 18.4 | 34 | 33.0 |
| Other n < 100 | 235 | 95 | 40.4 | 37 | 15.7 | 103 | 43.8 |
Most frequent conventional drugs according to age group and gender
| Medication [ATC classification] | Total | Gender | Age (y) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | 60-74 | 75-79 | > 80 | ||||||||
| N | % | n | % | n | % | n | % | n | % | n | % | |
| AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM [C09] | 1218 | 7.2 | 469 | 8.3 | 749 | 6.7 | 714 | 7.7 | 208 | 7.4 | 296 | 6.2 |
| ANALGESICS [N02] | 945 | 5.6 | 298 | 5.3 | 647 | 5.8 | 571 | 6.1 | 78 | 2.8 | 296 | 6.2 |
| PSYCHOLEPTICS [N05] | 823 | 4.9 | 281 | 5.0 | 541 | 4.8 | 400 | 4.3 | 144 | 5.2 | 279 | 5.8 |
| DIURETICS [C03] | 795 | 4.7 | 266 | 4.7 | 529 | 4.7 | 301 | 3.2 | 157 | 5.6 | 337 | 7.0 |
| BETA BLOCKING AGENTS [C07] | 740 | 4.4 | 275 | 4.9 | 465 | 4.1 | 453 | 4.9 | 116 | 4.2 | 171 | 3.6 |
| PSYCHOANALEPTICS [N06] | 711 | 4.2 | 242 | 4.3 | 469 | 4.2 | 329 | 3.5 | 135 | 4.8 | 247 | 5.1 |
| CARDIAC THERAPY [C01] | 648 | 3.8 | 205 | 3.6 | 358 | 3.2 | 215 | 2.3 | 116 | 4.1 | 317 | 6.6 |
| ANTI-PARKINSON DRUGS [N04] | 643 | 3.8 | 363 | 6.4 | 280 | 2.5 | 296 | 3.2 | 153 | 5.5 | 194 | 4.0 |
| ANTITHROMBOTIC AGENTS [B01] | 559 | 3.3 | 245 | 4.3 | 314 | 2.8 | 205 | 2.2 | 117 | 4.2 | 237 | 4.9 |
| ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS [M01] | 552 | 3.3 | 148 | 2.6 | 404 | 3.6 | 316 | 3.4 | 78 | 2.8 | 158 | 3.3 |
| DRUGS FOR ACID RELATED DISORDERS [A02] | 506 | 3.0 | 150 | 2.6 | 356 | 3.2 | 300 | 3.2 | 57 | 2.0 | 149 | 3.1 |
| CALCIUM CHANNEL BLOCKERS [C08] | 489 | 2.9 | 191 | 3.4 | 298 | 2.6 | 208 | 2.2 | 125 | 4.5 | 156 | 3.2 |
| THYROID THERAPY [H03] | 440 | 2.6 | 63 | 1.1 | 377 | 3.4 | 319 | 3.4 | 61 | 2.2 | 60 | 1.2 |
| DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES [R03] | 438 | 2.6 | 171 | 3.0 | 267 | 2.4 | 226 | 2.4 | 100 | 3.6 | 112 | 2.3 |
| DRUGS USED IN DIABETES [A10] | 426 | 2.5 | 167 | 3.0 | 259 | 2.3 | 274 | 2.9 | 76 | 2.7 | 76 | 1.6 |
| MINERAL SUPPLEMENTS [A12] | 422 | 2.5 | 79 | 1.4 | 343 | 3.0 | 254 | 2.7 | 44 | 1.6 | 124 | 2.6 |
| ANTIBIOTICS [J01] | 366 | 2.2 | 115 | 2.0 | 251 | 2.2 | 205 | 2.2 | 64 | 2.3 | 97 | 2.0 |
| LIPID MODIFYING AGENTS [C10] | 333 | 2.0 | 141 | 2.5 | 192 | 1.7 | 237 | 2.5 | 54 | 1.9 | 42 | 0.9 |
| Other n < 300 | 5856 | 34.6 | 1792 | 31.7 | 4150 | 36.9 | 3480 | 37.4 | 912 | 32.6 | 1464 | 30.4 |
Multivariate logistic regression: factors associated with anthroposophic remedies
| Factor | AOR (95% CI) |
|---|---|
| Follow-up | 1 |
| First | 1.65 (1.52 - 1.79)* |
| GP | 1 |
| Internal medicine | 1.49 (1.40 - 1.58)* |
| Other | 0.76 (0.70 - 0.84)* |
| 0.97 (0.97 - 0.98)* | |
| male | 1 |
| female | 1.35 (1.27 - 1.43)* |
| Hypertensive diseases [I10-I15] | 0.36 (0.32 - 0.39)* |
| Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, and related tissue [C00-C75] | 4.54 (4.12 - 4.99)* |
| Malignant neoplasms of ill-defined, secondary, and unspecified sites [C76-C80] | 2.90 (2.54 - 3.30)* |
| Arthropathies [M00-M25] | 1.36 (1.19 - 1.55)* |
| Chronic lower respiratory diseases [J40-J47] | 0.59 (0.50 - 0.69)* |
| Diabetes mellitus [E10-E14] | 0.17 (0.14 - 0.22)* |
| Episodic and paroxysmal disorders [G40-G47] | 0.53 (0.45 - 0.63)* |
| Ischaemic heart diseases [I20-I25] | 0.71 (0.60 - 0.83)* |
| Extrapyramidal and movement disorders [G20-G26] | 0.46 (0.37 - 0.58)* |
| Dorsopathies [M40-M54] | 1.34 (1.16 - 1.55)* |
| Metabolic disorders [E70-E90] | 0.17 (0.13 - 0.22)* |
| Disorders of thyroid gland [E00-E07] | 0.54 (0.45 - 0.64)* |
| Hypertensive diseases [I10-I15] * age | 1.03 (1.02 - 1.04)* |
| Extrapyramidal and movement disorders [G20-G26] * age | 1.04 (1.02 - 1.07)* |
* OR significant different from 1; ** continuous centered variable
Figure 2Odds ratios for the use of anthroposophic remedies for hypertensive disease and extrapyramidal and movement disorders stratified by age groups